Cost-effectiveness of long-acting injectable cabotegravir-rilpivirine as HIV treatment per virally-suppressed persons in a San Francisco clinic: an intermediary outcome analysis.
Marseille E, Walker RS, Hickey MD, Grochowski J, Mayorga-Munoz F, Oskarsson J, Imbert E, Shiels M, Szumowski JD, Neilands TB, Johnson MO, Gandhi M, Christopoulos KA
